BTK and myeloid sarcoma: Additional phase 2 and phase 3 clinical trials are planned/underway for evobrutinib (NCT02975349, NCT04338022, and NCT04338061) and tolebrutinib (NCT04411641, NCT04410991, NCT04410978, and NCT04458051), as well as other BTK inhibitors, including fenebrutinib (NCT05119569, NCT04586010, NCT04586023, and NCT04544449), orelabrutinib (NCT04711148), remibrutinib (NCT05147220 and NCT05156281), and BIIB061 (NCT04079088) for relapsing and progressive forms of MS (118, 132–145).